BioSpace News Archive

SELLAS Life Sciences Group, Inc . today reported its financial results for the quarter ended September 30, 2021 and provided a business update.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the following updates.

Novan, Inc., announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, joined by a pediatric dermatology thought leader, will participate in the Virtual Investor Roundtable Event on Wednesday, November 17, 2021 at 1:00 PM ET.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of significant results from a pivotal study of abivertinib on 227 heavily pretreated NSCLC patients in the journal Clinical Cancer Research, authored by Dr. Yi-Long Wu, distinguished professor of Guangdong Lung Cancer Institute, awardee of the prestigious “International Association for the Study of Lung Cancer (IASLC) Scientific Award” in 2017, and the principal investigator of the study.

Treadwell Therapeutics, today announced a presentation for the Company’s CFI-402411 program, an oral, first-in-class inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) a negative regulator of immune cell activation, at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Abbott (NYSE: ABT) today announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott’s investigational Aveir leadless pacemaker in patients with certain abnormal heart rhythms.

The American Joint Replacement Registry, the cornerstone of the American Academy of Orthopaedic Surgeons Registry Program, released its 2021 Annual Report on hip and knee arthroplasty procedural trends, and patient outcomes at the American Association of Hip and Knee Surgeons’ 2021 Annual Meeting.

DURECT Corporation announced the presentation of data at the American Association for The Study of Liver Diseases The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis in the U.S. of approximately 19% or approximately 4.8% per year between 2015 and 2018.

Apollo Endosurgery, Inc., a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that management will participate in four upcoming investor conference events.

Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.